Brewer Honore (walruspound1)

9) based on the VAS back pain to 99m (z-score of 1.0) based on the ZCQ physical function scale. The average MCID of the 6WT was 92m (z-score of 1.0). Based on the average MCID of raw 6WD values or standardized z-scores, 53% or 49% of patients classified as 6-week responders to surgery for lumbar DDD, respectively. The MCID for the 6WT in lumbar DDD patients is variable, depending on the calculation technique. We propose a MCID of 92m (z-score of 1.0), based on the average of all three methods. Using a z-score as MCID allows for the standardization of clinically meaningful change and attenuates age- and sex-related differences. 3. 3. The rapid development of electromechanical and robotic devices has profoundly influenced neurorehabilitation. Growth in the scientific and technological aspects thereof is crucial for increasing the number of newly developed devices, and clinicians have welcomed such growth with enthusiasm. Nevertheless, improving the standard for the reporting clinical, technical, and normative aspects of such electromechanical and robotic devices remains an unmet need in neurorehabilitation. Accordingly, this study aimed to analyse the existing literature on electromechanical and robotic devices used in neurorehabilitation, considering the current clinical, technical, and regulatory classification systems. Within the CICERONE Consensus Conference framework, studies on electromechanical and robotic devices used for upper- and lower-limb rehabilitation in persons with neurological disabilities in adulthood and childhood were reviewed. We have conducted a literature search using the following databases MEDLINE, Cochrane Lif the technical and functional details, along with high-quality RCT studies. Millions of human beings have suffered in the epidemic of coronavirus disease 2019 (COVID-19), but until now the effective treatment methods have been limited. This study aimed to evaluate the efficacy and safety of short-wave diathermy (SWD) treatment for moderate COVID-19 patients. A prospective, double-blind, randomized controlled clinical study. Inpatients unit of a COVID-19 specialized hospital. Forty-two patients with moderate COVID-19 were randomly allocated at a 21 ratio to two groups the SWD group and the control group. Participants of the SWD group received SWD treatment, and participants of the control group received placebo SWD treatment for one session per day, 10 minutes per session, for no more than 14 days. Both groups were given standard care treatment. Primary outcome was the rate of clinical improvement according to a sevencategory ordinal scale. Secondary outcomes included the rate of computed tomography (CT) improvement and the rate of potential adverse events. Clinical impr19 patients. Clinically relevant information is lacking regarding the efficacy and safety of SWD for patients with COVID-19. This study provides the first evidence that SWD is a promising adjuvant therapy for COVID-19. Clinically relevant information is lacking regarding the efficacy and safety of SWD for patients with COVID-19. This study provides the first evidence that SWD is a promising adjuvant therapy for COVID-19. Turning difficulties has been reported in stroke patients, but most studies have indicated no differences in turning direction regarding turn time or steps. Recent evidence shows that turning difficulty may correlate with trunk control. Trunk flexibility and strength are considered essential to trunk control, but their association with turning performance has not been elucidated. The study investigated the differences in turning direction in terms of turn duration and angular velocity and the relationship between turning performance and trunk function in patients with chronic stroke. Cross-